For an intermediate FAP expression indication, such as colon cancer (median H-Score: 20), 6% of the patient population would achieve at least 90% of the maximum pharmacological effect with the reference molecule, whereas 39% would achieve this effect with a molecule with a 10-fold increase in FAP-binding affinity. The gene discussed is FAP; the disease is malignant colon neoplasm.